Drugs / BBV-152 ANTIGEN ADJUVATED WITH ALGEL-IMDG
BBV-152 ANTIGEN ADJUVATED WITH ALGEL-IMDG
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05639998 | Sep 2021 → Mar 2022 | COVID-19 | Bharat Biotech International Limited | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04918797 | May → Aug 2021 | COVID-19 | Bharat Biotech International Limited | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05142319 | Oct 2021 → Jun 2023 | COVID-19 | Tan Tock Seng Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05522335 Comparator | Apr → Jul 2022 | COVID-19 | Bharat Biotech International Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05567471 Comparator | Feb → May 2022 | COVID-19 | Bharat Biotech International Limited | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBV-152 ANTIGEN ADJUVATED WITH ALGEL-IMDG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802199 ↗ |
| Known as | BBV152 | “125 participants will be recruited and administered with a booster dose of BBV152 (COVAXIN) vaccine, in individuals previously vaccinated with COVISHIELD.” NCT05567471 ↗3“BBV152 (Covaxin™) is a whole-virion inactivated SARS-CoV-2 vaccine mixed with an immune adjuvant.” PMID 39241318 ↗ Sep 2024 “an inactivated COVID-19 vaccine, BBV152 (COVAXIN; Bharat Biotech International, Hyderabad, India)” PMID 35717995 ↗ Jun 2022 “BBV152 (COVAXIN®) With BBV154 (Adenoviral Intranasal COVID-19 Vaccine)” NCT05639998 ↗ |
| Known as | Covaxin | “Group 2 (COVAXIN®): In this group, 160 participants will be recruited and administered with COVAXIN® vaccine on day 0 and on day 28 via intramuscular route.” NCT05522335 ↗6“either intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154) or licensed intramuscular vaccine, Covaxin®” PMID 37596281 ↗ Aug 2023 “BBV152 (Covaxin™) is a whole-virion inactivated SARS-CoV-2 vaccine mixed with an immune adjuvant.” PMID 39241318 ↗ Sep 2024 |
| Modality | Vaccine | “Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)” NCT04918797 ↗ |
| Route | Intramuscular | “administered with adult formulation of BBV152 as two 0·5 mL intramuscular doses” PMID 35717995 ↗ Jun 2022 |